olivLaw · European equity research
Cvc Capital Partners PLC CVC.AS
Netherlands · Euronext Amsterdam · Vertical: Listed companies from Netherlands
At the close of 06 Nov 2026, Cvc Capital Partners PLC (CVC.AS) stock was 14.46 EUR (−0.48% on the day), with market capitalisation 15.4 bn EUR, P/E 18.8 on diluted EPS of 0.77 EUR over the last 12 months, beta 1.08, 52-week range 10.75–15.75 EUR.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 68.9
- strong (55–70)
- Bollinger (20, 2)
- 11.19 – 14.88
- in the upper half of the band · %B 0.89 · band width 28.3%
- SMA 50 / 200
- 13.00 / 13.10
- mixed trend
- MACD (12, 26, 9)
- 0.47 / 0.22
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +19.8% | −0.2% | +20.0 pp | — |
| 3 months | −7.8% | −5.4% | −2.4 pp | — |
| 6 months | +8.6% | +4.4% | +4.3 pp | — |
| Year to date | +1.1% | +6.5% | −5.3 pp | — |
| 1 year | +4.3% | +10.0% | −5.7 pp | −0.7% |
| 3 years | unavailable | +48.6% | unavailable | +0.3% |
| 5 years | unavailable | +41.4% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 50 percentile of its own 2-quarter history (min 18.6, median 53.6, max 88.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | 280.5 m | 225.3 m | 1.2 bn |
| Net income YoY | unavailable | −19.7% | +425.1% |
| Diluted EPS | 0.39 | 0.24 | 0.77 |
| Diluted EPS YoY | unavailable | −38.5% | +220.8% |
| net % | unavailable | unavailable | unavailable |
| Free cash flow | 342.6 m | 672.4 m | 627.1 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 721.2 m EUR
- Financial debt
- 1.6 bn EUR
- Net debt
- 908.0 m EUR
- Equity
- 2.2 bn EUR
- Total assets
- 5.2 bn EUR
- Debt / equity
- 0.72x
- Current ratio
- 2.10x
- ROE
- 58.4%
- ROA
- 22.6%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating income | 332.9 m | 348.6 m | 1.3 bn | esef· 18 Mar 2026verified |
| Depreciation & amortisation | 26.0 m | 125.0 m | 183.7 m | esef· 18 Mar 2026verified |
| EBITDA | 358.9 m ≈ | 473.7 m ≈ | 1.4 bn ≈ | esef· 18 Mar 2026derived |
| Interest expense | 31.3 m | 53.0 m | 56.6 m | esef· 18 Mar 2026verified |
| Pre-tax income | 312.5 m | 308.5 m | 1.2 bn | esef· 18 Mar 2026verified |
| Income tax | 9.8 m | 350.0 k | -3.2 m | esef· 18 Mar 2026verified |
| Net income | 280.5 m | 225.3 m | 1.2 bn | esef· 18 Mar 2026verified |
| Diluted EPS | 0.39 | 0.24 | 0.77 | esef· 18 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 100.7 m | 618.3 m | 721.2 m | esef· 18 Mar 2026verified |
| Receivables | 57.8 m | 203.4 m | 273.5 m | esef· 18 Mar 2026verified |
| Current assets | 158.5 m | 821.6 m | 994.7 m | esef· 18 Mar 2026verified |
| Property, plant & equipment, net | 17.5 m | 178.7 m | — | esef· 15 Apr 2025verified |
| Total assets | 1.9 bn | 5.3 bn | 5.2 bn | esef· 18 Mar 2026verified |
| Short-term debt | 6.9 m | 82.1 m | 99.1 m | esef· 18 Mar 2026verified |
| Long-term debt | 1.4 bn | 1.6 bn | 1.5 bn | esef· 18 Mar 2026verified |
| Current liabilities | 102.2 m | 443.9 m | 472.7 m | esef· 18 Mar 2026verified |
| Total liabilities | 2.3 bn | 3.5 bn | 3.0 bn | esef· 18 Mar 2026verified |
| Equity | -392.9 m | 1.8 bn | 2.2 bn | esef· 18 Mar 2026verified |
| Shares outstanding at year end | 719.2 m | 938.7 m | 1.1 bn | esef· 18 Mar 2026derived |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 346.3 m | 689.1 m | 655.7 m | esef· 18 Mar 2026verified |
| Capex | 3.7 m | 16.8 m | 28.6 m | esef· 18 Mar 2026verified |
| Free cash flow | 342.6 m ≈ | 672.4 m ≈ | 627.1 m ≈ | esef· 18 Mar 2026derived |
| Investing cash flow | 126.6 m | -248.1 m | -75.7 m | esef· 18 Mar 2026verified |
| Financing cash flow | -491.2 m | 62.6 m | -455.3 m | esef· 18 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 61 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 15.4 bn EUR
Key indicators
Coverage and freshness
Score by group
- Quality73
- Balance sheet75
- Valuation44
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 7.39 – 19.10 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDA9.40 – 16.15 (Mid 11.99)6 companies used · median multiple 9.5x · quartiles 7.6x – 12.6xARCAD.AS, BAMNB.AS, BNJ.AS, BRNL.AS, CMCOM.AS, HAVAS.AS
- Peers: P/E7.39 – 19.10 (Mid 10.59)17 companies used · median multiple 13.8x · quartiles 9.6x – 24.8xAALB.AS, ACOMO.AS, AD.AS, ADYEN.AS, AKZA.AS, ARCAD.AS, ASM.AS, ASML.AS, AXS.AS, BAMNB.AS, BNJ.AS, CRBN.AS, CTAC.AS, ECMPA.AS, FFARM.AS, HAL.AS, HAVAS.AS
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Neutral profile · Score 61/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 35.0% | 96 (vs peers) | 16% |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | 53.0% | 33 (on a fixed band) | 9% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 0.6x | 50 (vs peers) | 16% |
| Interest coverage · Balance sheet | 22.2x | 100 (on a fixed band) | 9% |
| Current ratio · Balance sheet | 2.1x | 100 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | 18.8x | 50 (vs peers) | 16% |
| EV/EBITDA · Valuation | 11.3x | 33 (vs peers) | 16% |
| FCF yield · Valuation | 4.1% | 51 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet75/100 · 3/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality73/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation44/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CVC CAPITAL PARTNERS PLC (CVC.AS). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: ROE 90.9%; net debt/EBITDA 0.6x.
The estimated value range is 8.39–17.62 EUR per share (median of 2 methods, agreement: same basis (multiples on one peer group, not independent confirmations)); assumptions are illustrative. Against the central value of 11.29 EUR, the price of 14.46 EUR leaves a potential of -21.9% (value / price − 1) and a margin of safety of -28.1% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 61/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 35.0%
- Interest coverage: 22.2x
- Current ratio: 2.1x
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): Net margin, Revenue CAGR 3Y, EPS CAGR 3Y, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Netherlands · same country · compared with 40 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ASML.ASASML Holding N.V. | 498.6 bn | 48.9 | 44.2% | 31.3% | +15.6% | +42% / +106% |
| DSFIR.ASDSM-Firmenich AG | 32.7 bn | 116.8 | 1.2% | 2.2% | +20.4% | +55% / +26% |
| ASM.ASASM International N.V. | 31.9 bn | 44.3 | 18.7% | 22.8% | +8.2% | +37% / +38% |
| AD.ASKoninklijke Ahold Delhaize N.V. | 30.9 bn | 13.7 | 15.3% | 2.5% | +3.4% | −4% / +29% |
| ADYEN.ASAdyen N.V. | 28.4 bn | 26.8 | 22.3% | 40.1% | +18.9% | −33% / −16% |
| HAL.ASHAL Trust | 15.3 bn | 9.6 | 10.5% | 12.8% | +1.2% | +21% / +46% |
| EXO.ASExor N.V. | 15.1 bn | — | -10.6% | — | −100.0% | +1% / −18% |
| BESI.ASBE Semiconductor Industries N.V. | 11.4 bn | 86.4 | 28.7% | 22.3% | −2.7% | +10% / +12% |
| AKZA.ASAkzo Nobel N.V. | 10.8 bn | 17.0 | 13.8% | 6.3% | −5.2% | +12% / −11% |
| AALB.ASAalberts N.V. | 4.4 bn | 24.8 | 7.2% | 5.7% | −5.3% | +45% / +11% |
| ARCAD.ASArcadis N.V. | 4.1 bn | 19.8 | 18.3% | 4.3% | −2.4% | +21% / +0% |
| BNJ.ASBanijay Group N.V. | 3.4 bn | 13.8 | 343.8% | 5.1% | +1.6% | −11% / −8% |
| BAMNB.ASKoninklijke BAM Groep N.V. | 3.3 bn | 42.0 | 9.1% | 1.3% | +2.9% | +47% / +403% |
| BFIT.ASBasic-Fit N.V. | 2.0 bn | 137.1 | 3.6% | 1.0% | +16.9% | +6% / +15% |
| HAVAS.ASHavas N.V. | 1.8 bn | 9.4 | 10.2% | 6.5% | +1.7% | +23% / unavailable |
| CRBN.ASCorbion N.V. | 1.6 bn | 8.3 | 27.3% | 14.9% | +1.9% | +39% / +55% |
| ECMPA.ASEurocommercial Properties N.V. | 1.4 bn | 11.2 | 5.9% | 45.4% | +4.2% | −4% / +19% |
| FUR.ASFugro N.V. | 963.7 m | — | -1.5% | -1.1% | −18.8% | −2% / −50% |
| ACOMO.ASAcomo N.V. | 681.5 m | 15.1 | 10.7% | 3.3% | +7.6% | −4% / +36% |
| FAST.ASFastned B.V. | 671.8 m | — | -28.2% | -21.7% | +66.1% | +62% / +26% |
| FFARM.ASForFarmers N.V. | 477.6 m | 9.6 | 14.5% | 1.6% | +14.8% | +21% / +122% |
| BRNL.ASBrunel International N.V. | 356.7 m | 116.8 | 1.0% | 0.3% | −10.8% | −12% / −34% |
| ALFEN.ASAlfen N.V. | 222.6 m | — | -0.1% | -0.0% | −10.7% | −3% / −78% |
| ENVI.ASEnvipco Holding N.V. | 219.9 m | — | -12.7% | -11.9% | −20.8% | −27% / +44% |
| CMCOM.ASCM.com N.V. | 192.5 m | — | -22.2% | -1.5% | −5.4% | +23% / −30% |
1- and 3-year price returns: for CVC.AS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
- CVC Capital Partners raises $10B for its largest secondaries fund yetYahoo Finance — News · 03 Sept 2026 · EN
- CVC Capital Partners Raises €3 billion for Mid-Market FundBloomberg Markets · 06 Jul 2026 · EN
Annual reports (ESEF)
- Annual report 202518 Mar 2026
- Annual report 202415 Apr 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.